Tecentriq Dosage

Generic name: atezolizumab
Drug class: Anti-PD-1 monoclonal antibodies

Medically reviewed by  A Ras MD.

 Recommended Adult Dosing

Dosage forms:  INJ

Special Note

[uses, dosing may vary]

Info: refer to institution protocols and pkg insert prior to prescribing for uses and dosing incl. toxicity-related dose adjustments

Urothelial carcinoma, locally advanced or metastatic

[1200 mg IV q3wk]

Alt: 840 mg IV q2wk or 1680 mg IV q4wk; Info: for cisplatin-ineligible pts w/ PD-L1-expressing tumor or platinum-ineligible pts regardless of PD-L1 status

Non-small cell lung CA, stage II-IIIA

[adjuvant tx, PD-L1-expressing dz, monotherapy]

Dose: 1200 mg IV q3wk for up to 1y; Start: after resection and platinum-based chemo; Alt: 840 mg IV q2wk for up to 1y or 1680 mg IV q4wk for up to 1y

Non-small cell lung CA, metastatic

[first-line tx, high PD-L1-expressing dz, monotherapy]

Dose: 1200 mg IV q3wk; Alt: 840 mg IV q2wk or 1680 mg IV q4wk; Info: for pts w/ no EGFR or ALK genomic tumor aberrations

[first-line tx, nonsquamous dz]

Dose: 1200 mg IV q3wk; Alt: 840 mg IV q2wk or 1680 mg IV x4wk; Info: for pts w/ no EGFR or ALK genomic tumor aberrations; part of multi-drug chemo regimen

[progressive dz, monotherapy]

Dose: 1200 mg IV q3wk; Alt: 840 mg IV q2wk or 1680 mg IV q4wk

Extensive stage small cell lung CA, first-line tx

[1200 mg IV q3wk]

Alt: 840 mg IV q2wk or 1680 mg IV q4wk; Info: part of multi-drug chemo regimen

Unresectable or metastatic hepatocellular CA, first-line tx

[1200 mg IV q3wk]

Alt: 840 mg IV q2wk or 1680 mg IV q4wk; Info: use w/ bevacizumab

Melanoma, unresectable or metastatic

[840 mg IV q2wk]

Start: after one 28-day cycle of cobimetinib and vemurafenib; Alt: 1200 mg IV q3wk or 1680 mg IV q4wk; Info: for pts w/ BRAF V600 mutation; use w/ cobimetinib and vemurafenib

ER/PR-negative HER2-negative breast CA, unresectable locally advanced or metastatic

[indication withdrawn in US]

Info: drug not shown to improve survival in pts w/ unresectable locally advanced or metastatic ER/PR-negative HER2-negative breast CA whose tumors express PD-L1

Renal dosing

eGFR >30: no adjustment; eGFR <30: not defined

HD/PD: not defined

Hepatic dosing

mild impairment: no adjustment; mod-severe impairment: not defined

SRC: NLM .